Select City
Long-term intravitreal injection programs deliver medication directly into the vitreous of the eye to treat retinal diseases such as AMD, diabetic macular edema, and retinal vein occlusion. Regular treatment cycles protect vision and prevent further damage.
Long-term intravitreal injection programs deliver medication directly into the vitreous of the eye ... Read More
Free Cab Facility
No-Cost EMI
Support in Insurance Claim
1-day Hospitalization
USFDA-Approved Procedure
Intravitreal injections are a cornerstone of modern retinal disease management. These injections deliver anti-VEGF agents, steroids, or other medications directly into the vitreous cavity of the eye. Conditions such as age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion, and neovascular disorders respond well to regular intravitreal therapy. A structured injection program involves scheduled treatment cycles, monitoring, and dose adjustments based on disease activity. Early enrollment in a long-term program significantly reduces the risk of severe vision loss.
Fill details to get actual cost
Long-term intravitreal injection programs offer several advantages for patients with retinal disease:
Common medications used in intravitreal injection programs include:
Intravitreal injection programs are used to manage:
Diet & Lifestyle Consultation
Post-Surgery Recovery Follow up
Free Cab Facility
24*7 Patient Support
Patients at higher risk of requiring long-term intravitreal therapy include those with:
Patients diagnosed with wet AMD, diabetic macular edema, or retinal vein occlusion with macular edema are ideal candidates. Those with active choroidal neovascularization or persistent subretinal fluid despite initial therapy benefit from structured long-term programs. Regular fundus imaging and OCT scans help determine candidacy and track treatment response.
Diagnosis before enrolling in an intravitreal injection program involves:
Long-term intravitreal programs typically begin with a loading phase of three monthly injections, followed by a maintenance phase with extended dosing intervals. The treat-and-extend and pro re nata (PRN) protocols adjust injection frequency based on disease activity seen on OCT and clinical examination. Most patients require ongoing monitoring and periodic injections for years.
The intravitreal injection procedure is performed under sterile conditions in a clinical setting:
After receiving an intravitreal injection, patients should follow these guidelines:
Although generally safe, intravitreal injections carry some risks:
The frequency depends on the condition and treatment protocol. Most programs begin with monthly injections for 3 months, then extend intervals based on OCT findings. Some patients need injections every 6 to 12 weeks long-term.
The procedure is generally well tolerated. Topical anesthetic drops numb the eye before the injection, so most patients feel minimal discomfort. Some may experience a mild pressure sensation or temporary burning after the procedure.
Intravitreal anti-VEGF injections do not cure macular degeneration but effectively control disease activity. Regular injections stabilize vision in most patients and can improve visual acuity in many cases when started early.
Missing an injection can allow disease activity to resume, leading to fluid accumulation and potential vision loss. It is important to reschedule as soon as possible and inform your retina specialist about any missed appointments.
Sameer Khan
Recommends
I had a retinal detachment scare and the emergency care at Healing Touch Hospital was outstanding.
trisha
Recommends
The Doctor is very experienced. Also staff is very helpful and cooperative.Thank you so much(pristyn care)for your support and guidance.
.svg)
.svg)
